Tae Won Kim

1.3k total citations · 1 hit paper
17 papers, 699 citations indexed

About

Tae Won Kim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Tae Won Kim has authored 17 papers receiving a total of 699 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Tae Won Kim's work include Colorectal Cancer Treatments and Studies (14 papers), Cancer Treatment and Pharmacology (7 papers) and Gastric Cancer Management and Outcomes (6 papers). Tae Won Kim is often cited by papers focused on Colorectal Cancer Treatments and Studies (14 papers), Cancer Treatment and Pharmacology (7 papers) and Gastric Cancer Management and Outcomes (6 papers). Tae Won Kim collaborates with scholars based in South Korea, United States and Australia. Tae Won Kim's co-authors include Kun‐Huei Yeh, Tianshu Liu, Hongming Pan, Shukui Qin, Yuxian Bai, Anh T. Le, Liwei Wang, Jen-Kou Lin, Feng Bi and Rui‐Hua Xu and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Tae Won Kim

15 papers receiving 691 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

2015 553 citations Jin Li, Shukui Qin et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Tae Won Kim

Since Specialization

Citations

This map shows the geographic impact of Tae Won Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tae Won Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tae Won Kim more than expected).

Fields of papers citing papers by Tae Won Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tae Won Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tae Won Kim. The network helps show where Tae Won Kim may publish in the future.

Co-authorship network of co-authors of Tae Won Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Tae Won Kim. A scholar is included among the top collaborators of Tae Won Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tae Won Kim. Tae Won Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Can AI-Based Video Analysis Help Evaluate the Performance of the Items in the Bayley Scales of Infant Development? 2025 ·Children ·(unknown), Tae Won Kim, Sumin Kim, (unknown), Jane Pei‐Chen Chang, June‐Goo Lee, Eun Jae Ko	0
2	Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164 2023 ·European Journal of Cancer ·Dung T. Le, Luis A. Díaz, Tae Won Kim, Eric Van Cutsem, Ravit Geva, Dirk Jäger, Hiroki Hara, Matthew Burge, Bert H. O’Neil, Petr Kavan, Takayuki Yoshino, Rosine Guimbaud, Hiroya Taniguchi, Elena Élez, Salah-Eddin Al-Batran, Patrick M. Boland, Yi Cui, Pierre Leconte, Patricia Marinello, Thierry André	46
3	BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC). 2023 ·Journal of Clinical Oncology ·Scott Kopetz, Takayuki Yoshino, Tae Won Kim, Harpreet Wasan, Eric Van Cutsem, Fortunato Ciardiello, Tim Maughan, Cathy Eng, Rona Yaeger, Jayesh Desai, (unknown), Tiziana Usari, A. Mori, Josep Tabernero	9
4	BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAF^V600E metastatic colorectal cancer (mCRC). 2023 ·Journal of Clinical Oncology ·Scott Kopetz, Takayuki Yoshino, Tae Won Kim, Rona Yaeger, Jayesh Desai, Harpreet Wasan, Eric Van Cutsem, Fortunato Ciardiello, Tim Maughan, Cathy Eng, Jeanne Tie, Élena Elez, Sara Lonardi, (unknown), Chin‐Hee Chung, Tiziana Usari, (unknown), Danielle Murphy, Josep Tabernero	14
5	O7-3 Pembrolizumab vs chemotherapy in MSI-H / dMMR metastatic colorectal cancer: KEYNOTE-177 final analysis Asia subgroup 2022 ·Annals of Oncology ·Takayuki Yoshino, Thierry André, Kai‐Keen Shiu, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, (unknown), Denis Smith, Rocio García‐Carbonero, Peter Gibbs, (unknown), Noriaki Adachi, David R. Fogelman, Patricia Marinello, Luis A. Díaz	1
6	BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAF^V600E) metastatic colorectal cancer (mCRC). 2022 ·Journal of Clinical Oncology ·Scott Kopetz, Takayuki Yoshino, Tae Won Kim, Jayesh Desai, Rona Yaeger, Eric Van Cutsem, Fortunato Ciardiello, Harpreet Wasan, Tim Maughan, Yuanyuan Zhang, Tiziana Usari, Chin‐Hee Chung, Xiaosong Zhang, Josep Tabernero	11
7	Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02). 2022 ·Journal of Clinical Oncology ·Kanwal Raghav, Takayuki Yoshino, Rosine Guimbaud, Ian Chau, Marc Van den Eynde, Joan Maurel, Jeanne Tie, Tae Won Kim, Kun‐Huei Yeh, Daniel Barrios, Kojiro Kobayashi, Emarjola Bako, Mehreteab Aregay, (unknown), Salvatore Siena	5
8	Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer 2022 ·Cancer Science ·Takayuki Yoshino, Thierry André, Tae Won Kim, Wei Peng Yong, Kai‐Keen Shiu, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J.A. Punt, Denis Smith, Rocio García‐Carbonero, Julia Alcaide, Peter Gibbs, Christelle de la Fouchardière, Fernando Rivera, Elena Élez, Dung T. Le, Noriaki Adachi, David R. Fogelman, Patricia Marinello, Luis A. Díaz	15
9	Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) stage IV colorectal cancer (CRC). 2022 ·Journal of Clinical Oncology ·Thierry André, (unknown), Mahmut Gümüş, Joong Bae Ahn, Lucjan Wyrwicz, Mariusz Kwiatkowski, Jong Gwang Kim, Şuayib Yalçın, Mehmet Alı Nahıt Şendur, (unknown), Pierre Leconte, David R. Fogelman, Tae Won Kim	2
10	Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02). 2021 ·Journal of Clinical Oncology ·Kanwal Raghav, Takayuki Yoshino, Rosine Guimbaud, Ian Chau, Marc Van den Eynde, Joan Maurel, Jeanne Tie, Tae Won Kim, Kun‐Huei Yeh, Daniel Barrios, Kojiro Kobayashi, Emarjola Bako, Mehreteab Aregay, Gerold Meinhardt, Salvatore Siena	14
11	Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial breakdown → 2015 ·The Lancet Oncology ·Jin Li, Shukui Qin, Rui‐Hua Xu, Thomas Yau, Brigette Ma, Hongming Pan, Jianming Xu, Yuxian Bai, Yihebali Chi, Liwei Wang, Kun‐Huei Yeh, Feng Bi, Ying Cheng, Anh T. Le, Jen-Kou Lin, Tianshu Liu, Dong Ma, Christian Kappeler, J. Kalmus, Tae Won Kim	553
12	Effects of regorafenib (REG) therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial. 2015 ·Journal of Clinical Oncology ·Jane Chang, Christopher Ngai, Dawn Odom, (unknown), Christian Kappeler, Rui‐Hua Xu, Shukui Qin, Tae Won Kim, Jin Li	2
13	Effects of regorafenib therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial. 2015 ·Journal of Clinical Oncology ·Shukui Qin, Tae Won Kim, Thomas Cheung Yau, Brigette Ma, Hongming Pan, Jianming Xu, Yuxian Bai, Liwei Wang, Kun‐Huei Yeh, Feng Bi, Ying Cheng, Tuấn Anh Lê, (unknown), Tianshu Liu, (unknown), Christian Kappeler, Jane Chang, Rui‐Hua Xu, Jin Li, (unknown)	2
14	A post-hoc health-related quality of life (HRQoL) analysis of patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial. 2015 ·Journal of Clinical Oncology ·Jane Chang, Dawn Odom, (unknown), Christian Kappeler, Rui‐Hua Xu, Shukui Qin, Tae Won Kim, Jin Li	3
15	Randomized Phase II Open-Label Study of mFOLFOX6 in Combination With Linifanib or Bevacizumab for Metastatic Colorectal Cancer 2014 ·Clinical Colorectal Cancer ·Bert H. O’Neil, Călin Cainap, Eric Van Cutsem, (unknown), Christos S. Karapetis, Jordan Berlin, Richard M. Goldberg, Qin Qin, Jiang Qian, Justin L. Ricker, (unknown), Mark D. McKee, Dawn M. Carlson, Tae Won Kim	17
16	Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer. 2012 ·Journal of Clinical Oncology ·Bert H. O’Neil, Călin Cainap, Eric Van Cutsem, В. А. Горбунова, Christos S. Karapetis, Jordan Berlin, Richard M. Goldberg, Qin Qin, Jiang Qian, Justin L. Ricker, Mark D. McKee, Dawn M. Carlson, Tae Won Kim	0
17	A Randomised Crossover Study Comparing Ramosetron plus Dexamethasone with Ramosetron Alone in the Prevention of Cisplatin-Induced Emesis 2005 ·Clinical Drug Investigation ·Jeong Hye Kim, Tae Won Kim, Min‐Hee Ryu, Heung Moon Chang, (unknown), Jung Shin Lee, Yoon‐Koo Kang	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact